Intravenous Catheters Market: as BD's CentroVena One consolidates the introducer needle, syringe, guidewire, and catheter into a single insertion platform, the central line placement technique used for nearly seven decades is facing its first genuine engineering redesign, so the competitive question in central venous access is shifting from incremental catheter material improvements toward whether a manufacturer can redesign the entire insertion workflow itself, and the winners will be companies that treat the insertion procedure, not just the catheter, as the product.

The global intravenous catheters market size was USD 10.9 Billion in 2025 and is expected to register a revenue CAGR of 7.0% during the forecast period. Market revenue growth is driven by factors such as safety-engineered catheter mandates converting injury-prevention features into baseline hospital procurement specifications, all-in-one insertion system platforms consolidating multiple procedural steps into a single device, and closed IV catheter systems expanding into emerging market hospital channels. The first driving factor is safety-engineered catheter mandates, as OSHA and comparable international regulations continue to push hospital procurement toward passive and active retraction and blood-control catheter designs. Peripherally inserted central catheters account for approximately 54% of total 2025 market revenue, reflecting the clinical centrality of PICC lines to extended vascular access therapy. The second driving factor is all-in-one insertion system platforms that consolidate the introducer needle, syringe, guidewire, and catheter into a single device, reducing procedural steps and insertion time. The third driving factor is closed IV catheter systems expanding into emerging market hospital channels, extending established manufacturer platforms beyond their historical developed-market base. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single all-in-one insertion platform redesign can displace the entire multi-component insertion kit a hospital previously purchased separately, which converts several distinct purchasing line items, needle, syringe, guidewire, and catheter, into one consolidated device purchase that captures the full value of what was previously a fragmented procurement relationship. Because central line insertion has followed largely the same multi-step technique for decades, a manufacturer that successfully redesigns the entire insertion workflow into a single validated platform captures not just the catheter revenue but the value of every component that platform replaces, converting a catheter sale into a full insertion-system sale. As a result, demand and revenue share in the central venous catheter segment are concentrating around manufacturers who can successfully commercialise all-in-one insertion platforms, and the forecast reflects this platform consolidation as a distinct driver of manufacturer revenue capture independent of underlying procedure volume growth. For instance, in April 2026, BD launched its CentroVena One Insertion System, the first all-in-one central venous catheter insertion device on the market, consolidating the introducer needle, syringe, guidewire, and catheter into a single platform and reducing procedural steps by approximately 30% and insertion time by approximately 50% relative to traditional methods in a head-to-head simulation study. These are some of the key factors driving revenue growth of the market.

Because catheter-related bloodstream infection remains a documented risk across peripheral, PICC, and central venous catheter types despite decades of design and technique improvement, hospitals continue to invest in infection prevention protocols and surveillance beyond the catheter itself, adding cost and complexity to vascular access programmes regardless of which device platform is selected.

Clinical technique variability is a second constraint, because insertion success rates and complication rates vary meaningfully with clinician experience and technique, which means even a superior device platform's real-world performance depends significantly on training and adoption discipline at the individual hospital level.

Reimbursement bundling for vascular access procedures is a third constraint, since many IV catheter insertions are reimbursed under bundled procedure codes that do not separately itemise premium device costs, which limits a hospital's ability to pass through the cost of advanced insertion systems even where they offer documented clinical and workflow advantages.

These factors substantially limit intravenous catheters market growth over the forecast period.

The clearest driver of demand is safety-engineered catheter mandates, as OSHA and comparable international regulations continue to push hospital procurement toward passive and active retraction and blood-control catheter designs across peripheral, PICC, and central line categories. A needlestick injury during catheter insertion carries both direct occupational health risk and liability exposure for hospitals, so regulatory mandate has converted safety-engineered design into a baseline procurement specification that continues to expand into catheter categories and regions not yet fully covered. Peripherally inserted central catheters account for approximately 54% of total 2025 market revenue, and B. Braun received FDA clearance for its Introcan Safety 2 Deep Access IV Catheter specifically to improve safety in historically difficult-access patients. The effect on the market is that safety-engineered penetration continues to rise across catheter categories even where overall procedure volume growth is more modest. These are some of the key factors driving revenue growth of the market.

The second driver is all-in-one insertion system platforms that consolidate the introducer needle, syringe, guidewire, and catheter into a single device, converting a multi-component procurement relationship into one consolidated platform purchase. Central line insertion has followed largely the same multi-step technique for decades, so a platform that reduces procedural steps and insertion time while incorporating safety-focused design elements addresses both a genuine workflow efficiency opportunity and a patient safety opportunity simultaneously. In April 2026, BD launched its CentroVena One Insertion System, the first all-in-one central venous catheter insertion device on the market, reducing procedural steps by approximately 30% and insertion time by approximately 50% relative to traditional methods according to a head-to-head simulation study published in The Journal of Emergency Medicine, and the device was accepted into the FDA's Safer Technologies Program for Medical Devices. The effect on the market is that manufacturer revenue capture per procedure is expanding as platforms consolidate previously separate component purchases into a single device sale. These are some of the key factors driving revenue growth of the market.

BD's CentroVena One reduces central line insertion steps by approximately 30% and insertion time by approximately 50% in simulation testing. The technique introduced nearly seven decades ago is facing its first genuine all-in-one platform redesign.

The third driver is the expansion of closed IV catheter systems into emerging market hospital channels, extending established manufacturer platforms beyond their historical developed-market commercial base. A closed IV catheter system reduces blood exposure risk during insertion and use, which is a genuine clinical advantage anywhere it is deployed, so extending an already-validated closed-system platform into new geographic markets lets a manufacturer capture incremental revenue without a new product development cycle. BD has expanded commercial distribution of its Nexiva Closed IV Catheter System into Asian and Latin American hospital markets, extending a platform previously concentrated in developed-market hospital systems. The effect on the market is that established closed-system catheter platforms are capturing incremental emerging-market revenue growth independent of any new product launch. These are some of the key factors driving revenue growth of the market.

However, the intravenous catheters market faces severe adoption constraints from catheter-related bloodstream infection risk that persists across all vascular access device types and clinical technique variability affecting insertion success rates.

Because catheter-related bloodstream infection remains a documented risk across peripheral, PICC, and central venous catheter types despite decades of design and technique improvement, hospitals continue to invest in infection prevention protocols and surveillance beyond the catheter itself, adding cost and complexity to vascular access programmes regardless of which device platform is selected.

Clinical technique variability compounds this, because insertion success rates and complication rates vary meaningfully with clinician experience and technique, which means even a superior device platform's real-world performance depends significantly on training and adoption discipline at the individual hospital level.

Reimbursement bundling for vascular access procedures is the third constraint, since many IV catheter insertions are reimbursed under bundled procedure codes that do not separately itemise premium device costs, which limits a hospital's ability to pass through the cost of advanced insertion systems even where they offer documented clinical and workflow advantages.

These factors substantially limit intravenous catheters market growth over the forecast period.

Based on product, the global intravenous catheters market is segmented into peripheral intravenous catheters, PICC lines, central venous catheters, and midline catheters. PICC lines hold the largest revenue share, because they serve extended-duration therapy needs that command higher per-unit pricing and more complex insertion procedures than standard peripheral catheters, which suits a market where extended vascular access therapy concentrates the largest revenue category. Peripheral intravenous catheters remain the highest-volume category by unit count given their use in the overwhelming majority of hospital admissions, but individually lower per-unit pricing keeps overall revenue share below PICC lines. Central venous catheters are expected to register the fastest revenue growth rate in the global intravenous catheters market over the forecast period, driven by BD's CentroVena One all-in-one insertion platform expanding the category's addressable market beyond its historical scope.

Based on material, the global intravenous catheters market is segmented into polyurethane and fluoropolymer IV catheters. Polyurethane holds the largest revenue share, because it remains the standard material for the majority of PICC and central venous catheter applications given its favourable biocompatibility and flexibility characteristics. Fluoropolymer catheters are expected to register the fastest revenue growth rate in the global intravenous catheters market over the forecast period, driven by their superior kink resistance and chemical compatibility for demanding infusion applications.

Based on type, the global intravenous catheters market is segmented into safety-engineered and conventional non-safety IV catheters. Safety-engineered catheters hold the largest revenue share, reflecting sustained OSHA and comparable international regulatory mandate across hospital procurement channels, which ties directly back to the regulatory mandate described in the market's primary demand driver. Safety-engineered catheters are also expected to register the fastest revenue growth rate in the global intravenous catheters market over the forecast period, driven by continued mandate expansion into markets and catheter categories not yet fully covered.

Based on regional analysis, the intravenous catheters market in North America accounted for largest revenue share in 2025. The United States leads because BD's CentroVena One launch specifically targets the US market as its initial commercial focus, and because BD, B. Braun, and ICU Medical all maintain their primary commercial presence in the US market. OSHA's Needlestick Safety and Prevention Act enforcement creates the strongest safety-engineered catheter mandate globally. The concentration of FDA clearance activity in the country also means new insertion platform technologies are typically launched in the United States first, before international expansion.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent the two largest national markets within the region, driven by expanding hospital infrastructure and rising acute care procedure volume. BD's expansion of its Nexiva Closed IV Catheter System into Asian hospital markets specifically targets this region's growth, which leaves considerably more room for growth than in the already catheter-saturated North American market.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. B. Braun, headquartered in Germany, maintains its primary global manufacturing and commercial base in Europe. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with BD's Nexiva Closed IV Catheter System expansion specifically targeting Latin American hospital markets. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the polyurethane and fluoropolymer materials that Latin American device distributors depend on, an effect expected to run through 2026 and slow intravenous catheter adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for intravenous catheter adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the safety-engineered procurement infrastructure needed to support advanced catheter platforms at scale.